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Background/Aims:  Few studies have investigated hepatitis A virus (HAV) seroepidemiology in Koreans with chronic liver disease 
(CLD). This study compared the prevalence of IgG anti-HAV between the general healthy population and patients with hepatitis 
B virus-related CLD (HBV-CLD), with the aim of identifying predictors of HAV prior exposure. Methods: In total, 1,319 patients 
were recruited between June 2008 and April 2010. All patients were tested for IgG anti-HAV, hepatitis B surface antigen (HBsAg), 
and antibodies to hepatitis C virus. The patients were divided into the general healthy population group and the HBV-CLD group 
based on the presence of HBsAg. The seroprevalence of IgG anti-HAV was compared between these two groups. Results: The 
age-standardized seroprevalence rates of IgG anti-HAV in the general healthy population and patients with HBV-CLD were 
52.5% and 49.1%, respectively. The age-stratified IgG anti-HAV seroprevalence rates for ages ≤19, 20-29, 30-39, 40-49, 50-59, 
and ≥60 years were 14.3%, 11.2%, 45.5%, 90.5%, 97.6% and 98.3%, respectively, in the general healthy population, and 0%, 
9.8%, 46.3%, 91.1%, 97.7%, and 100% in the HBV-CLD group. In multivariate analysis, age (<30 vs. 30-59 years: OR=19.339, 
95% CI=12.504-29.911, P<0.001; <30 vs. ≥60 years: OR=1060.5, 95% CI=142.233-7907.964, P<0.001) and advanced status 
of HBV-CLD (OR=19.180, 95% CI=4.550-80.856, P<0.001) were independent predictors of HAV prior exposure. Conclusions: 
The seroprevalence of IgG anti-HAV did not differ significantly between the general-healthy-population and HBV-CLD groups. An 
HAV vaccination strategy might be warranted in people younger than 35 years, especially in patients with HBV-CLD. (Korean J 
Hepatol 2010;16:362-368)
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INTRODUCTION
Hepatitis A is usually self-limited and has a benign clinical 
course. It is usually asymptomatic in children, whereas it causes 
clinically  apparent  disease  in  the  majority  of  adults,  rarely 
progressing to fulminant hepatic failure.
1 In particular, the old 
age and chronic liver disease (CLD) have been known to be risk 
factors for fulminant hepatic failure.
2 Therefore, hepatitis A virus 
(HAV) vaccination is recommended for patients with CLD.
Improvements in the socioeconomic status and general public 
health of Korea have led to a shift in the seroprevalence of hep-
atitis A from hyperendemic region to lower one.
3 Paradoxically, 
the number of children and young adults who are susceptible to 
HAV infection has been gradually increased, resulting in the re-
cent rapid rise of symptomatic hepatitis A. Currently, hepatitis A 
has become one of the most common causes of acute viral in-
fection in Korean adults.
3,4 Although the prevalence of chronic 
hepatitis B virus (HBV) infection has been declined after the in-
troduction of universal vaccination, it is still the most important 
cause of CLD in Korea.
5 Accordingly, the seroprevalence of hep-
atitis A in patients with HBV-related CLD has been of interest. 
However, there are few studies about HAV seroepidemiology in 
Korean population with CLD,
6,7 and no studies have compared 
the seroprevalence of IgG anti-HAV between general healthy Sang Ho Lee, et al. Prevalence of IgG anti-HAV  363
population and patients with HBV-related CLD.
This study was aimed to evaluate the seroprevalence of IgG 
anti-HAV in Korean patients with HBV-related CLD and ana-
lyzed it as compared with general healthy population. Thus, we 
attempted to provide the objective data about the HAV vacci-
nation strategy in patients with HBV-related CLD and to identify 
the predictors of prior HAV exposure.
PATIENTS AND METHODS
Patients and study design
We retrospectively analyzed the medical records of 1,319 pa-
tients aged 15 years or older who underwent tests for hepatitis B 
surface  antigen  (HBsAg),  anti-hepatitis  C  virus  antibody 
(anti-HCV) and IgG anti-HAV, between June 2008 and April 
2010. Of them, 622 patients who were negative to both HBsAg 
and anti-HCV and had no past history of other liver diseases such 
as alcoholic hepatitis and autoimmune hepatitis were classified 
as general healthy population. Remaining 697 patients who were 
positive to HBsAg regardless of the presence of anti-HCV were 
classified as those with HBV-related CLD. The seroprevalence 
of IgG anti-HAV was evaluated according to age and sex at the 
time  of  laboratory  tests  and  compared  between  the  general 
healthy population and the patients with HBV-related CLD.
The severity of liver disease was classified as follows: 1) in-
active HBsAg carrier was defined as those who were positive to 
HBsAg for more than six months, were negative to hepatitis B e 
antigen, had a serum level of HBV DNA<10
4 copies/mL and per-
sistently had normal levels of serum ALT for more than one year, 
2) chronic hepatitis B (CHB) patient was defined as those who 
had a serum level of HBV DNA>10
4 copies/mL, had serum ALT 
level elevated persistently or intermittently and had a lack of evi-
dences demonstrating the presence of liver cirrhosis and hep-
atocellular carcinoma,
8 3) liver cirrhosis was diagnosed by his-
tology or ultrasonographic/CT imaging features, supplemented 
with clinically relevant portal hypertension (esophageal and/or 
gastric  varices,  ascites,  splenomegaly  with  a  platelet  count 
of<100,000/mm
3) or hepatic encephalopathy, 4) hepatocellular 
carcinoma was made according to the guidelines of American 
Society for the Study of Liver Diseases, which was based on the 
imaging study and serum alpha-fetoprotein levels.
9
The current study was conducted in compliance with the dec-
laration of Helsinki and approved by the Institutional Review 
Board (IRB) of our medical institution.
Statistics
Student’s  t-test  for  continuous  variables,  and  chi  squared 
analysis, Fisher’s exact test for categorical variables were used 
where appropriate. Age standardization was done using the di-
rect methods where the 2005’s statistics of Korean population 
were served as the standard population. Then, the prevalence of 
IgG anti-HAV was evaluated using Cochran-Mantel-Haenszel 
methods. To identify the factors affecting the HAV prior ex-
posure, a multivariate logistic regression analysis was performed 
using variables such as age, sex, the presence of HBsAg and the 
severity of liver diseases. On multivariate analysis, the age of the 
patients were divided into three groups (<30, 30~59, ≥60) and 
the  severity  of  liver  diseases  were  divided  into  two  groups. 
Patients with liver cirrhosis or hepatocellular carcinoma were 
classified as severe cases. General healthy population, inactive 
HBsAg carrier and CHB patients were classified as mild cases. A 
value  of  P<0.05  was  considered  statistically  significant. 
Statistical  analysis  was  performed  using  SPSS  version  18.0 
(Chicago, IL, USA).
RESULTS
Baseline characteristics of the patients
The number of general healthy population and that of patients 
with HBV-related CLD were 622 and 697, respectively. Mean 
age was 39 years (14.5 years, S.D.) and 46.6 years (13.4 years, 
S.D.), respectively. The proportion of male patients was 45.2% 
(281/622) and 64.6% (450/697), respectively. There were sig-
nificant  differences  in  age  and  sex  between  the  two  groups 
(P<0.001). Of patients with HBV-related CLD, a total of 14 pa-
tients had a superinfection with chronic hepatitis C (Table 1).
Com parison  of  the  seroprevalence  of  IgG  anti- HAV 
between  general  healthy  population  and  patients 
with HBV-related CLD
The  overall  positive  rate  for  IgG  anti-HAV  was  54.3% 
(338/622) in general healthy population and 75.6% (527/697) in 
patients with HBV-related CLD with a significant difference 
(P<0.001). Following the age standardization, however, it was 
found to be 52.5% and 49.1%, respectively. This difference did 
not reach a statistical significance (OR 1.026, 95% CI 0.735~1.433, 
P=0.880). The age-stratified IgG anti-HAV seroprevalence in 
general healthy population for ages≤19, 20~29, 30~39, 40~49, 
50~59, ≥60 was 14.3% (2/14), 11.2% (19/169), 45.5% (92/202), 364  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Table  1.  Baseline  characteristics  of  the  study  population 
Characteristics General  population CHB P-value
No.  of  patients 622 697
Mean  age±SD 39.0±14.5 46.6±13.4 <0.001
Age  (years)  interval,  no.(%) <0.001
<20 14 (2.3%) 2 (0.3%)
20-29 169 (27.2%) 61 (8.8%)
30-39 202 (32.5%) 175 (25.1%)
40-49 95 (15.3%) 169 (24.2%)
50-59 83 (13.3%) 171 (24.5%)
≥60 59 (9.5%) 119 (17.1%)
Male  sex-no.  (%) 281 (45.2%) 450 (64.6%) <0.001
Cause  of  liver  disease,  no.  (%)
HBV 683 (98.0%)
HBV+HCV   14 (2.0%)
Status  of  HBV  related  CLD,  no.  (%)
Inactive  carrier 340 (48.8%)
Chronic  hepatitis 220 (31.6%)
LC 96 (13.4%)
HCC 41 (5.9%)
CHB,  chronic  hepatitis  B;  HBV,  hepatitis  B  virus;  HCV,  hepatitis  C  virus;  CLD,  chronic  liver  disease;  LC,  liver  cirrhosis;  HCC, 
hepatocellular  carcinoma.
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Figure  1.  Age-stratified  IgG  anti-HAV  prevalence  rates  in  the 
general  healthy  population  and  patients  with  HBV-CLD.  The 
prevalence rates in the various decade age groups did not differ 
significantly  between  these  two  groups.
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Figure 2. Age-stratified IgG anti-HAV prevalence rates in male 
and female subjects. The prevalence did not differ significantly 
with  sex.
90.5% (86/95), 97.6% (81/83), and 98.3% (58/59), respectively. It 
was 0% (0/2), 9.8% (6/61), 46.3% (81/175), 91.1% (154/169), 
97.7% (167/171), and 100.0% (119/119), respectively, in pa-
tients with HBV-related CLD (Fig. 1).
The sex-related positive rate for IgG anti-HAV was 68.8% 
(503/731) in male patients and 61.6% (362/588) in female pa-
tients (P=0.006). After the age standardization, however, it was 
found to be 54.1% and 48.7%, respectively. This difference did not 
reach a statistical significance (OR 1.072, 95% CI 0.772~1.487, 
P=0.680). Therefore, there was no significant difference in the 
age-stratified seroprevalce of IgG anti-HAV according to sex 
(Fig. 2). In general healthy population, the positive rate for IgG 
anti-HAV between male patients (60.5%, 170/281) and female 
patients (49.3%, 168/341) was significantly different (P=0.006), 
however, this difference did not reach a statistical significance 
(55.1% in male vs. 48.0% in female; OR 1.324, 95% CI 0.848~ 
2.069, P=0.217) after the age standardization. In patients with 
HBV-related CLD, it was found to be 74.0% (333/450) and 
78.5% (194/247), respectively. It was not significantly different Sang Ho Lee, et al. Prevalence of IgG anti-HAV  365
Table  2.  Multivariate  analysis  of  the  factors  related  to  prior  HAV  exposure
Variables OR 95%  CI P-value
HBsAg
            Negative 1.0
            Positive 1.246 0.931~1.668 0.139
Age
            <30 1.0
            30-59 19.339 12.504~29.911 <0.001
            ≥60 1,060.552 142.233~7907.964 <0.001
Sex
            Female 1.0
            Male 1.018 0.762~1.360 0.906
Status  of  HBV  related  CLD
            Mild 1.0
            Severe 19.180 4.550~80.856 <0.001
HAV, hepatitis A virus; OR, odd ratio; CI, confidence interval; HBsAg, hapatitis B surface antigen; HBV, hepatitis B virus; CLD, 
chronic  liver  disease.
(P=0.197), and following the age standardization, it was also not 
changed (48.6% in male vs. 49.9% in female; OR 0.817, 95% CI 
0.494-1.352, P=0.433).
Independent predictors for prior HAV exposure
To identify the factors affecting the positive rate for IgG anti- 
HAV, a multivariate analysis was performed using variables such 
as age, sex, the presence of HBsAg, and the severity of liver 
diseases. Age (<30 vs. 30-59: OR 19.339, 95% CI 12.504~29.911, 
P<0.001; <30 vs. ≥60: OR 1060.5, 95% CI 142.233~7907.964, 
P<0.001) and the severity of liver diseases (OR 19.180, 95% CI 
4.550-80.856, P<0.001) were identified as independent factors 
for HAV prior exposure. Sex (OR 1.018, 95% CI 0.762~1.360, 
P=0.906)  and  the  presence  of  HBsAg  (OR  1.246,  95%  CI 
0.931~1.668, P=0.139) were not associated with HAV prior 
exposure (Table 2).
DISCUSSION
Improvements in the socioeconomic status and general public 
health of Korea have led to a shift in the seroprevalence of hep-
atitis A.
3 In the early 1980s, the positive rate of antibody against 
HAV has been reported to exceed 90% in adults aged 20 years or 
older.
10 Thereafter, it has been gradually decreased. Paradoxically, 
the prevalence of apparent hepatitis A infection has been in-
creased in adolescents and young adults. Symptomatic hepatitis 
A has been rapidly increasing on a nationwide scale since 2000, 
and it has become a legally-designated infectious disease. At the 
present, as an infectious disease for sentinel surveillance, the sta-
tus of its occurrence has been collected by the Korea Centers for 
Disease Control and Prevention (KCDC).
4 According to epi-
demiologic data by the KCDC, there were 320 cases of acute 
hepatitis A in 2002, 307 cases in 2003 and 357 cases in 2004. 
Since 2005, however, it has begun to rise strikingly, showing 826 
cases in 2005, 2,130 cases in 2006, 2,168 cases in 2007 and 7,878 
cases in 2008. Then, it reached 15,041 cases in 2009, showing 
the explosive increase in the incidence of acute hepatitis A.
4 
These results indicate that the incidence of acute hepatitis A 
occurred at an incidence of almost 30 cases per 100,000 Korean 
people, which urges to promote HAV vaccination for childhood 
and high risk groups.
The superinfection of hepatitis virus infection in patients with 
CLD may aggravate the underlying liver disease. Korea is an 
endemic area of HBV infection.
11 and superinfection with HAV 
in HBV-related CLD remains problematic in these days. In Thai, 
it has been reported that the incidence and mortality of fulminant 
hepatic failure were 55% and 25% in cases of acute hepatitis A 
superinfection in HBsAg carriers.
12 Chu et al. from Taiwan 
reported that risks of developing fulminant hepatic failure were 
approximately  nine  times  higher  in  HBsAg  carriers  than 
noncarriers.
13 According to a study about the prevalence of hep-
atitis A, which was conducted in Shanghai and the USA, Keeffe 
reported that the mortality was approximately 6-58 times higher 
in HBsAg-positive patients as compared with HBsAg-negative 366  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Table  3.  Anti-HAV  seropositivity  in  the  Korean  population
Reference
No.
Study  period Populaltion Subject  number
Prevalence  (%)  of  IgG  anti-HAV  according  to 
age  group  (yr)
<10 11~20 21~30 31~40 >40
6 2006 CLD 267 22.2 26.1 72.2 98.7
7 2005 CLD 419 16.7 77.8 98.1
19 2006 Hospital  control 987 48.2 10.8 15.8 73.2 97.7
20 2006 Healthy  adults 250 2 72 95.3
21 2003~2006 CLD 307 7.1 8.9 46.5 92.6
22 2002~2006 Hospital  control 4,299 40.7 21.6 32.8 79.8 97.9
23 2005~2006 Soldiers 200 2
24 2006~2007 Police  officers 507 0.6
25 2004~2005 Hospital  control 472 1.7 0 40.5 82.1 >95
26 2006 Hospital  control 643 18.5 34.4 88.9 98.4
Our  study 2008~2010 HBV-CLD 697 0 9.8 46.3 95.9
Our  study 2008~2010 General  population 622 14.3 11.2 45.5 94.9
HAV,  hepatitis  A  virus;  CLD,  chronic  liver  disease;  HBV,  hepatitis  B  virus.
patients.
14 In a Korean study,
15 it was demonstrated that 
HBV-related  CLD  is  related  to  the  poor  prognosis  of  acute 
hepatitis. As mentioned above, considering the marked increase 
in the incidence of apparent hepatitis A due to the epidemiologic 
shift and a poor prognosis in patients with HBV-related CLD 
who have HAV superinfection, it is imperative that the vacci-
nation  policy  for  hepatitis  A  be  established  in  patients  with 
HBV-related CLD. To date, however, studies of HAV seroepi-
demiology in populations including HBV-related CLD in Korea 
are scarce.
According to the current study, the positive rate for IgG 
anti-HAV was relatively higher in patients with HBV-related 
CLD and male patients as compared with general healthy pop-
ulation  and  female  patients,  respectively.  Following  the  age 
standardization, however, there was no significant difference in 
the positive rate according to the presence of HBsAg and sex. 
This might be because elderly people accounted for a greater part 
of patients with HBV-related CLD and male patients. There was 
no significant difference in the age-specific seroprevalence of 
IgG anti-HAV between the two groups and multivariate analysis 
showed that sex and the presence of HBsAg were not associated 
with HAV prior exposure. These results were in agreement with 
reports, made by Hindman et al.,
16 that hepatitis A and hepatitis B 
are mutually exclusive to each other. Besides, the above results 
were comparable with reports of Saab et al.,
17 that the positive 
rate for IgG anti-HAV was higher in patients with HBV-related 
CLD as compared with general healthy population in univariate 
analysis, but there was no significant correlation in multivariate 
analysis. Also in Korea, Cho et al.
18 also reported that the age was 
the independent factor affecting HAV prior exposure, which was 
consistent with our findings.
In respect to the positive rate for IgG anti-HAV, our study 
showed similar results to other Korean reports (Table 3).
6,7,19-26 
The positive rate for IgG anti-HAV was found to be higher than 
90% in patients aged 45 years or older. Most of these patients were 
exposed to HAV previously and then spontaneously acquired an 
immunity against hepatitis A. In patients aged 29 years or 
younger, the positive rate for IgG anti-HAV was found to be lower 
than 15%. These results suggest that most of these patients were 
devoid of immunity. In patients aged between 30 and 44 years 
old, the positive rate for IgG anti-HAV varied ranging from 28 to 
86%. These results indicate that the selective vaccination strat-
egy would be warranted for these age groups. According to Saab 
et al.,
27 in cases in which the positive rate for IgG anti-HAV was 
higher than 35%, the selective vaccination had an excellent 
profile  of  cost-effectiveness  as  compared  with  the  universal 
vaccination. According to the current study, the prevalence of 
IgG anti-HAV in general healthy population aged between 30 
and 34 years old and those aged between 35 and 39 years old was 
found to be 28.8% (32/111) and 65.9% (60/91), respectively. 
And, the prevalence of IgG anti-HAV in patients with HBV- 
related CLD aged between 30 and 34 years old and those aged 
between 35 and 39 years old was found to be 27.4% (23/84) and 
63.7% (58/91), respectively. Based on our results, it can be Sang Ho Lee, et al. Prevalence of IgG anti-HAV  367
inferred that the universal vaccination should be used for patients 
aged 34 years or younger and the selective vaccination should be 
used for patients aged 35 years or older. This might be beneficial 
from a cost-effective perspective.
Our results also showed that not only the age but also the 
severity of liver disease had a prognostic value for a past history 
of exposure to hepatitis A infection. It is therefore imperative that 
an active vaccination be performed for younger patients aged 35 
years or younger, especially, patients with HBV-related CLD 
who had no advanced liver diseases such as liver cirrhosis or 
hepatocellular carcinoma, because they are expected to have a 
lack of the immunity against hepatitis A. Besides, considering 
that patients with HBV-related CLD who have a superinfection 
with acute hepatitis A have a poor clinical course as compared 
with general healthy population, the vaccination based on an 
active  screening  test  should  be  performed  for  patients  with 
HBV-related CLD who were aged 35 years or older. Our results 
might present the baseline data for establishing the appropriate 
vaccination strategy for general healthy population and patients 
with HBV-related CLD.
The limitations of the current study are that it was difficult to 
identify a statistical significance in young age group because the 
number of enrolled patients aged 19 years or younger was 
smaller than those of other age groups. Also, because the current 
study was conducted in a single center in Seoul and did not 
include patients with non-HBV-related CLD, it could not be 
representative of total Korean people and could not be generally 
applied to all the Korean patients with CLD. Considering not 
only that there was no significant difference in the seropreva-
lence of IgG anti-HAV between the current study and other pre-
vious Korean reports but also that HBV was the most common 
cause of CLD in Korea, however, our results might present the 
baseline epidemiologic data for IgG anti-HAV in Korean patients 
with CLD.
In conclusion, our results showed that there was an epidemio-
logic shift where the positive rate for IgG anti-HAV was 
decreased as compared with the past in adults in their 20s and 
30s. It was also confirmed that the prevalence of IgG anti-HAV 
was not increased in patients with HBV-related CLD as com-
pared with general healthy population. This might be used as a 
baseline epidemiologic data for estimating the prevalence of IgG 
anti-HAV in general healthy population and patients with CLD in 
Korea. This should also be followed by a nationwide epidemio-
logical study. Besides, the age and the severity of hepatic dis-
eases were found to be variables affecting the HAV prior 
exposure, based on which the HAV vaccination strategy should 
be established.
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